PTHS
Pelthos Therapeutics Inc. (PTHS) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
A 413-day cash conversion cycle, driven by 400 days of inventory, implies heavy working-capital drag versus peers with faster turns and tighter cash generation.
Negative interest coverage and negative net debt to EBITDA suggest earnings are not yet covering financing costs, leaving PTHS more exposed than better-capitalized peers.
Days sales outstanding of 122 days indicates slower receivable collection, which can pressure liquidity and limit flexibility relative to peers with shorter collection cycles.
Current and quick ratios near 2.0 and 1.3 provide some near-term liquidity, but they do not offset the structural cash inefficiency versus more efficient peers.
Opportunities
A current ratio near 2.0 gives PTHS more short-term liquidity headroom than many peers, supporting operations while working-capital normalization improves.
Negative net debt to EBITDA indicates a net cash position, which can reduce refinancing pressure versus leveraged peers if operating performance stabilizes.
If inventory turns improve from the current 400-day level, cash release could materially lift free cash flow relative to peers with already efficient cycles.
The liquidity buffer may help PTHS absorb demand volatility better than peers with tighter balance sheets, preserving positioning in a cyclical environment.
Overall Score
PTHS is constrained by severe working-capital inefficiency and weak interest coverage versus peers, while a relatively solid liquidity position and net cash profile provide some offset.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Pelthos Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
